GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ACRO Biomedical Co ACBM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.03

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$101,146

FY2016FY2025

Free cash flow

−$196,306

FY2016FY2025

Shareholders' equity

−$386,964

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue——$658,500$658,500$1.2m$687,964$193,536$8.0m$510,000—
Gross profit——$140,500$140,500$259,500$159,404$12,096$833,400$51,000—
Research and development$4.8m—$10.1m$10.1m$5.3m—————
Operating income−$154,024−$37,958−$15.9m−$15.9m−$7.7m−$130,463−$422,751$515,550−$2,248−$43,428
Net income−$101,146−$42,297−$15.9m−$15.9m−$7.7m−$117,453−$371,604$419,660−$2,248−$43,428
Diluted earnings per share-0.00-0.00-0.26-0.26-0.13-0.00-0.010.01-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$14,098$31,974$687,486$687,486$761,077$998,053$932,126$1.5m$548,310$2,533
Cash and short-term investments$4,098—$5,852—$95,248$18,123$911$1,148$36,810$2,533
Total liabilities$401,062$326,946$201,116$201,116$117,370$312,185$133,887$240,675$36,979$17,326
Debt$325,512—$25,719—$50,432$24,500$46,310$141,136$36,379$10,000
Shareholders' equity−$386,964−$294,972$486,370$486,370$643,707$685,868$798,239$1.2m$511,331−$14,793
Shares outstanding60m60m60m60m60m48m48m48m48m47m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$196,302−$36,692−$147,481−$147,481$299,335−$199,460−$59,709−$140,419−$463,344−$34,742
Capital spending−$4—−$1———————
Free cash flow−$196,306−$36,692−$147,482−$147,481$299,335−$199,460−$59,709−$140,419−$463,344−$34,742

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue————−$360,000———
Gross profit————−$64,000———
Operating income−$17,554−$60,271−$16,377−$115,099−$13,614−$8,934−$9,468−$9,106
Net income−$21,356−$43,774$42,526−$117,809−$15,562−$10,301−$10,673−$10,229
Diluted earnings per share-0.00-0.000.00-0.00-0.00-0.00-0.00-0.00
Total assets$3,648$3,873$14,098$4,323$53,277$25,175$31,974$38,676
Cash and short-term investments$3,648$3,873$4,098$4,323$26———
Debt$385,387$375,108$325,512$300,360$255,304———
Shareholders' equity−$444,789−$427,235−$386,964−$432,619−$317,520−$303,906−$294,972−$285,504

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-78.7%3.4%12.5%
Net income-81.5%-2.9%7.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-13.2-1.0-0.4-3.7-4.4-91.1-36.133.9
Price to sales——9.688.528.015.669.41.8

Share price return

Finished calendar years

20252024202320222021202020192018
Return0%-99%-88%51%150%-26%8%48%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 3-for-1 split · 22 May 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.